Kaposi's sarcoma

Summary

Kaposi’s sarcoma (MONDO:0005055) is a cancer with 2 cohort genes (1 CIViC-evidence somatic driver; 2 ClinVar predisposition records) and 73 clinical trials. Top therapeutic interventions include propranolol, nelfinavir, and tenofovir disoproxil.

At a glance

• Classification: Cancer
• Prevalence: 1-9 / 100 000 (Europe) [Orphanet-validated]
• Cohort genes: 2
• ClinVar variants: 2
• Phenotypes (HPO): 26
• Clinical trials: 73

Clinical features

Epidemiology

Prevalence records

26 prevalence record(s), Orphanet, top 20 (validated / broadest geography first):

Type	Class	Value	Geography	Validation
Annual incidence	1-9 / 1 000 000	0.34	Europe	Validated
Lifetime Prevalence	1-9 / 100 000	2.11	Europe	Validated
Point prevalence	1-9 / 100 000		Europe	Validated
Annual incidence	<1 / 1 000 000	0.051	Austria	Validated
Annual incidence	<1 / 1 000 000	0.075	Belgium	Validated
Annual incidence	<1 / 1 000 000	0.099	Bulgaria	Validated
Annual incidence	<1 / 1 000 000	0.092	Czech Republic	Validated
Annual incidence	<1 / 1 000 000	0.065	Estonia	Validated
Annual incidence	<1 / 1 000 000	0.014	Finland	Validated
Annual incidence	<1 / 1 000 000	0.076	Germany	Validated
Annual incidence	<1 / 1 000 000	0.027	Norway	Validated
Annual incidence	<1 / 1 000 000	0.043	Poland	Validated
Annual incidence	<1 / 1 000 000	0.05	Slovakia	Validated
Annual incidence	<1 / 1 000 000	0.056	Slovenia	Validated
Annual incidence	1-9 / 1 000 000	0.133	Croatia	Validated
Annual incidence	1-9 / 1 000 000	0.111	Ireland	Validated
Annual incidence	1-9 / 1 000 000	0.108	Latvia	Validated
Annual incidence	1-9 / 1 000 000	0.112	Lithuania	Validated
Annual incidence	1-9 / 1 000 000	0.597	Malta	Validated
Annual incidence	1-9 / 1 000 000	0.915	Portugal	Validated

Signs & symptoms

Clinical features (HPO)

26 HPO clinical features (Orphanet curated; top 26 by frequency):

HPO ID	Term	Frequency
HP:0005353	Recurrent herpes	Obligate (100%)
HP:0001034	Hypermelanotic macule	Very frequent (80-99%)
HP:0002814	Abnormality of the lower limb	Very frequent (80-99%)
HP:0008069	Neoplasm of the skin	Very frequent (80-99%)
HP:0012733	Macule	Very frequent (80-99%)
HP:0000479	Abnormal retinal morphology	Frequent (30-79%)
HP:0001028	Hemangioma	Frequent (30-79%)
HP:0001298	Encephalopathy	Frequent (30-79%)
HP:0001743	Abnormality of the spleen	Frequent (30-79%)
HP:0002721	Immunodeficiency	Frequent (30-79%)
HP:0005523	Lymphoproliferative disorder	Frequent (30-79%)
HP:0008940	Generalized lymphadenopathy	Frequent (30-79%)
HP:0011024	Abnormality of the gastrointestinal tract	Frequent (30-79%)
HP:0200034	Papule	Frequent (30-79%)
HP:0200036	Skin nodule	Frequent (30-79%)
HP:0000988	Skin rash	Occasional (5-29%)
HP:0001004	Lymphedema	Occasional (5-29%)
HP:0001392	Abnormality of the liver	Occasional (5-29%)
HP:0001824	Weight loss	Occasional (5-29%)
HP:0001945	Fever	Occasional (5-29%)
HP:0002014	Diarrhea	Occasional (5-29%)
HP:0002088	Abnormal lung morphology	Occasional (5-29%)
HP:0005293	Venous insufficiency	Occasional (5-29%)
HP:0011793	Neoplasm by anatomical site	Occasional (5-29%)
HP:0012378	Fatigue	Occasional (5-29%)
HP:0200035	Skin plaque	Occasional (5-29%)

Identifiers

Disease identifiers

Field	Value
Canonical name	Kaposi’s sarcoma
Mondo ID	MONDO:0005055
EFO	EFO:0000558
MeSH	D012514
Orphanet	33276
DOID	DOID:8632
ICD-10-CM	C46
NCIT	C9087
SNOMED CT	109385007
UMLS	C0036220
MedGen	11321
GARD	0006814
MedDRA	10023284
Is cancer (heuristic)	yes

Also known as: anal Kaposi’s sarcoma · cardiac Kaposi’s sarcoma · central nervous system Kaposi’s sarcoma · conjunctival Kaposi’s sarcoma · corneal Kaposi’s sarcoma · cutaneous Kaposi’s sarcoma · esophageal Kaposi’s sarcoma · gallbladder Kaposi’s sarcoma · gastric Kaposi’s sarcoma · HHV8 · human herpesvirus 8 · intestinal Kaposi’s sarcoma · Kaposi sarcoma · Kaposi sarcoma herpesvirus · Kaposi’s sarcoma · Kaposi’s sarcoma (disease) · Kaposi’s sarcoma of anus · Kaposi’s sarcoma of central nervous system · Kaposi’s sarcoma of esophagus · Kaposi’s sarcoma of gastrointestinal sites (+22 more)

Data availability: 2 ClinVar variants · 1 HPO phenotype · 8 cell lines.

Disease family

An umbrella term covering 4 Mondo subtypes.

Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › infectious disease › viral infectious disease › Kaposi’s sarcoma

Related subtypes (40): Whitewater Arroyo hemorrhagic fever, exanthema subitum, Zika virus congenital syndrome, common wart, viral labyrinthitis, viral gastritis, vaccinia, viral esophagitis, contagious pustular dermatitis, epidemic pleurodynia, herpangina, human T-lymphotropic virus 1 infectious disease, lumpy skin disease, milker’s nodule, molluscum contagiosum, Newcastle disease, pharyngoconjunctival fever, pseudorabies, Reoviridae infectious disease, immunodeficiency 32B, focal epithelial hyperplasia, neurolymphomatosis, viral myositis, virus-associated trichodysplasia spinulosa, infective dermatitis associated with HTLV-1, congenital varicella syndrome, viral hemorrhagic fever, arbovirus fever, human infection by orthopoxvirus, congenital Epstein-Barr virus infection, rabies, arbovirus infection, viral eye infection, viral infection of central nervous system, viral respiratory tract infection, Parvoviridae infectious disease, COVID-19–associated multisystem inflammatory syndrome in children, primary viral infectious disease, disease arising from reactivation of latent virus, human betaherpesvirus 5 infectious disease

Subtypes (4): iatrogenic Kaposi’s sarcoma, classic Kaposi sarcoma, endemic Kaposi sarcoma, colorectal Kaposi sarcoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

ClinVar germline variants

2 retrieved; paginated sample, class counts are floors:

1 other; risk factor, 1 conflicting classifications of pathogenicity

ClinVar	Variant (HGVS)	Gene	Classification	Review
14718	NC_000007.14:g.22727026C>G	IL6	other; risk factor	no assertion criteria provided
2077514	NM_182641.4(BPTF):c.6035T>C (p.Ile2012Thr)	BPTF	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 0 · Orphanet: 3 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

Somatic driver evidence (intOGen + CIViC, cohort fanout)

Gene	intOGen role	Cancer types	CIViC
IL6			CIViC #2970

Orphanet rare-disease linkage (cohort genes)

Gene	Orphanet ID	Rare disease
BPTF	Orphanet:529962	17q24.2 microdeletion syndrome
BPTF	Orphanet:686482	BPTF-related intellectual disability-facial dysmorphism-skeletal anomalies syndrome
IL6	Orphanet:85414	Systemic-onset juvenile idiopathic arthritis

Cohort genes → proteins

2 cohort genes, 2 distinct canonical proteins.

Evidence partition

Subset	Genes
multi_evidence	2

Cohort genes (full)

Symbol	HGNC	Ensembl	UniProt	Name	Evidence
BPTF	HGNC:3581	ENSG00000171634	Q12830	Nucleosome-remodeling factor subunit BPTF	clinvar
IL6	HGNC:6018	ENSG00000136244	P05231	Interleukin-6	clinvar

Cohort function summary

Lead sentence per gene, UniProt-curated.

Symbol	Protein name	Function (lead sentence)
BPTF	Nucleosome-remodeling factor subunit BPTF	Regulatory subunit of the ATP-dependent NURF-1 and NURF-5 ISWI chromatin remodeling complexes, which form ordered nucleosome arrays on chromatin and facilitate access to DNA during DNA-templated processes such as DNA replication, transcrip…
IL6	Interleukin-6	Cytokine with a wide variety of biological functions in immunity, tissue regeneration, and metabolism.

Protein-family classification

Druggable: 0 · Difficult: 1 · Unknown: 1 · Druggable fraction: 0.0

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

Family	Genes	Fold	FDR
Transcription factor	1	4.1×	0.455
Other/Unknown	1	0.9×	0.805

Per-gene assignment

Symbol	Family	Druggable?	EC	InterPro (top 3)
BPTF	Transcription factor	no		Bromodomain, Znf_PHD, Znf_FYVE_PHD
IL6	Other/Unknown	no		IL-6-like, 4_helix_cytokine-like_core, IL6/GCSF/MGF_CS

Expression context

Cohort genes with no expression data: 0.

2 cohort genes are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

Bucket	Genes
narrow (1-5 tissues)	0
moderate (6-20)	0
broad (>20)	2
unknown	0

Top tissues across cohort

Tissue	Cohort genes
cortical plate	1
sural nerve	1
ventricular zone	1
cartilage tissue	1
gall bladder	1
vena cava	1

Per-gene tissue summary (top 30)

Symbol	Bgee breadth	FANTOM5 breadth	SCXA	Top tissues
BPTF	290	ubiquitous	marker	sural nerve, ventricular zone, cortical plate
IL6	200	ubiquitous	marker	cartilage tissue, vena cava, gall bladder

Protein interactions among cohort

Intra-cohort edges: 0.

Hub genes (top 10 by interactor count)

Symbol	Interactor count
IL6	9,239
BPTF	2,682

Structural data

PDB: 2 · AlphaFold-only: 0 · No structure: 0

Cohort genes with PDB structures (top 30)

Symbol	UniProt	PDB entries
BPTF	Q12830	45
IL6	P05231	17

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 12. Enrichment computed across 2 evidence-associated genes (1 with Reactome annotation).

Pathways by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

Pathway	Cohort genes	Fold	FDR	Sample cohort genes
MAPK1 (ERK2) activation	1	1142.0×	0.003	IL6
CD163 mediating an anti-inflammatory response	1	1142.0×	0.003	IL6
MAPK3 (ERK1) activation	1	1038.2×	0.003	IL6
Interleukin-6 signaling	1	951.7×	0.003	IL6
Transcriptional Regulation by VENTX	1	265.6×	0.007	IL6
ADORA2B mediated anti-inflammatory cytokines production	1	253.8×	0.007	IL6
Interleukin-10 signaling	1	233.1×	0.007	IL6
Activation of STAT3 by cadherin engagement	1	163.1×	0.009	IL6
Interleukin-4 and Interleukin-13 signaling	1	102.9×	0.011	IL6
Post-translational protein phosphorylation	1	100.2×	0.011	IL6
Senescence-Associated Secretory Phenotype (SASP)	1	99.3×	0.011	IL6
Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs)	1	86.5×	0.012	IL6

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 2 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO term	Cohort genes	Fold	FDR	Sample cohort genes
regulation of astrocyte activation	1	4213.0×	0.005	IL6
glucagon secretion	1	4213.0×	0.005	IL6
neutrophil apoptotic process	1	2808.7×	0.005	IL6
hepatic immune response	1	2808.7×	0.005	IL6
positive regulation of interleukin-21 production	1	2808.7×	0.005	IL6
regulation of vascular endothelial growth factor production	1	2106.5×	0.005	IL6
regulation of glucagon secretion	1	2106.5×	0.005	IL6
regulation of microglial cell activation	1	2106.5×	0.005	IL6
negative regulation of primary miRNA processing	1	2106.5×	0.005	IL6
positive regulation of apoptotic DNA fragmentation	1	1404.3×	0.005	IL6
vascular endothelial growth factor production	1	1203.7×	0.005	IL6
response to peptidoglycan	1	1203.7×	0.005	IL6
positive regulation of type B pancreatic cell apoptotic process	1	1203.7×	0.005	IL6
negative regulation of chemokine production	1	1053.2×	0.005	IL6
positive regulation of B cell activation	1	1053.2×	0.005	IL6
hepatocyte proliferation	1	1053.2×	0.005	IL6
inflammatory response to wounding	1	1053.2×	0.005	IL6
germinal center B cell differentiation	1	842.6×	0.005	IL6
positive regulation of receptor signaling pathway via STAT	1	842.6×	0.005	IL6
negative regulation of interleukin-1-mediated signaling pathway	1	842.6×	0.005	IL6
negative regulation of lipid storage	1	766.0×	0.005	IL6
T-helper 17 cell lineage commitment	1	766.0×	0.005	IL6
positive regulation of T-helper 2 cell cytokine production	1	766.0×	0.005	IL6
neutrophil mediated immunity	1	702.2×	0.005	IL6
positive regulation of acute inflammatory response	1	702.2×	0.005	IL6
T follicular helper cell differentiation	1	702.2×	0.005	IL6
regulation of neuroinflammatory response	1	702.2×	0.005	IL6
positive regulation of leukocyte adhesion to vascular endothelial cell	1	702.2×	0.005	IL6
positive regulation of leukocyte chemotaxis	1	648.1×	0.005	IL6
positive regulation of platelet aggregation	1	648.1×	0.005	IL6

Therapeutics

Drugs indicated for this disease

3 approved, 2 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Development status
Alitretinoin	Approved (phase 4)
INTERFERON ALFA-2B	Approved (phase 4)
Paclitaxel	Approved (phase 4)
Daunorubicin	Phase 3 (in late-stage trials)
Doxorubicin	Phase 3 (in late-stage trials)

Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Abacavir, Bevacizumab, Digoxin, Everolimus, Ipilimumab, Ixazomib Citrate, Lamivudine, Lenvatinib, Lopinavir, Maraviroc, Nivolumab, Pembrolizumab, Pomalidomide, Propranolol, Ritonavir, Talimogene Laherparepvec, Zidovudine.

Drug target analysis

Approved (phase 4): 1 · Phase ≥3: 1 · Phased (≥1): 2 · Undrugged: 0

Druggability breadth: 2 of 2 evidence-associated genes (100%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Genes with an approved drug

The molecule shown is one approved compound that hits the gene — not necessarily a drug of choice or one indicated for this disease.

Symbol	Example approved molecule
IL6	PREDNISOLONE

Top cohort targets by molecule count

Symbol	Molecules	Max phase
IL6	3	4
BPTF	2	2

Drugs targeting cohort genes (top 30)

Molecule	Max phase	Targets in cohort
PREDNISOLONE	4	IL6
IPIDACRINE	2	BPTF
BI-2536	2	BPTF
FOSDAGROCORAT	2	IL6
BI 653048	1	IL6

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 0.

Cohort genes with ChEMBL bioactivity (full, sorted by assay count)

Symbol	Assays	Type breakdown
BPTF	125	Binding:123, Functional:2
IL6	16	Binding:16

Cohort genes with high screening signal

≥100 ChEMBL assays — a studied-ness signal; see Therapeutics for approved-drug status.

Symbol	ChEMBL assays
BPTF	125

Pharmacogenomics

Cohort genes with a PharmGKB record: 2; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Drug repurposing candidates

5 approved/phased drugs hit cohort targets but don’t yet appear in disease-level clinical trials. Target-inhibition rationale is strongest for cancer driver genes; a bioactivity hit is a screening signal, not a treatment claim.

Compound	Max phase	Cohort target (bioactivity)
PREDNISOLONE	4	IL6
IPIDACRINE	2	BPTF
BI-2536	2	BPTF
FOSDAGROCORAT	2	IL6
BI 653048	1	IL6

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

Tier	Definition	Genes	Symbols
A	Approved (phase 4 drug)	1	IL6
B	Phased (≥1) drug, not yet approved	1	BPTF
C	Druggable family + PDB, no drug	0
D	Druggable family + AlphaFold only, no drug	0
E	Difficult family or no structure, no drug	0

Undrugged target profiles

0 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

Clinical trials & evidence

Clinical trials

Clinical trials: 73.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	24
Not specified	23
PHASE1	12
PHASE1/PHASE2	8
PHASE4	2
PHASE3	2
EARLY_PHASE1	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00380770	PHASE4	COMPLETED	HIV/AIDS Kaposis Sarcoma: Comparison of Response to HAART vs HAART Plus CXT
NCT00444379	PHASE4	COMPLETED	Anti-Retrovirals for Kaposi’s Sarcoma
NCT05411237	PHASE3	NOT_YET_RECRUITING	Paclitaxel and Pegylated Liposomal Doxorubicin for Treatment of HIV-related Kaposi Sarcoma
NCT01352117	PHASE3	COMPLETED	Antiretroviral Therapy (ART) Alone or With Delayed Chemo Versus ART With Immediate Chemo for Limited AIDS-related Kaposi’s Sarcoma
NCT01419561	PHASE2	RECRUITING	Natural History Study of the KSHV Inflammatory Cytokine Syndrome (KICS)
NCT04303117	PHASE1/PHASE2	RECRUITING	PDS01ADC Monotherapy and in Combination With M7824 in Advanced Kaposi Sarcoma
NCT04305691	PHASE2	RECRUITING	Trial of Ixazomib for Kaposi Sarcoma
NCT04941274	PHASE1/PHASE2	RECRUITING	Abemaciclib in Patients With HIV-associated and HIV-negative Kaposi Sarcoma
NCT05797662	PHASE2	NOT_YET_RECRUITING	A Study of Propranolol to Treat Kaposi Sarcoma
NCT06052618	PHASE2	RECRUITING	Phase II Study of Pacritinib in Kaposi Sarcoma Herpesvirus (KSHV)-Associated Multicentric Castleman Disease and KSHV-Associated Inflammatory Cytokine Syndrome (KICS)
NCT06445166	PHASE2	RECRUITING	Propranolol for the Treatment of Kaposi Sarcoma in Adults
NCT06638931	PHASE2	RECRUITING	Agnostic Therapy in Rare Solid Tumors
NCT07308886	PHASE2	RECRUITING	Recombinant Glycosylated Human Interleukin-7 (CYT107) for the Treatment of Kaposi Sarcoma in Participants With HIV and Immune Non-Response (REGIMENKS HIV)
NCT07576725	PHASE2	NOT_YET_RECRUITING	Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial
NCT00019188	PHASE1/PHASE2	COMPLETED	Interleukin-12 in Treating Patients With AIDS-Related Kaposi’s Sarcoma
NCT00055237	PHASE2	COMPLETED	Bevacizumab to Treat Kaposi’s Sarcoma in HIV-Positive and HIV-Negative Patients
NCT00064142	PHASE2	COMPLETED	Halofuginone Hydrobromide in Treating Patients With HIV-Related Kaposi’s Sarcoma
NCT00194467	PHASE2	COMPLETED	Suppression of Oral HHV8 Shedding With Valganciclovir
NCT00686842	PHASE1/PHASE2	TERMINATED	PTC299 in Treating Patients With HIV-Related Kaposi Sarcoma
NCT01057121	PHASE1/PHASE2	COMPLETED	Lenalidomide in Treating Patients With AIDS-Associated Kaposi’s Sarcoma
NCT01067690	PHASE2	COMPLETED	Treatment With Indinavir and Chemotherapy for Advanced Classical Kaposi’s Sarcoma
NCT01154452	PHASE1/PHASE2	COMPLETED	Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma
NCT01276236	PHASE2	COMPLETED	Effects of Maraviroc (MVC) on HIV-related Kaposi’s Sarcoma (KS)
NCT01412515	PHASE2	TERMINATED	A Phase II Study With Tumor Molecular Pharmacodynamic (MPD) Evaluation of Oral mTOR-inhibitor Everolimus (RAD001) 10 mg Daily in Patients Suffering From Classic or Endemic Kaposi’s Sarcoma
NCT01495598	PHASE1/PHASE2	COMPLETED	Pomalidomide for Kaposi Sarcoma in People With or Without HIV
NCT02029430	PHASE2	COMPLETED	A Study to Investigate ALDOXORUBICIN in HIV-infected Subjects With Kaposi’s Sarcoma
NCT02137564	PHASE2	WITHDRAWN	Gamma Secretase Inhibitor PF-03084014 in Treating Patients With AIDS-Associated Kaposi Sarcoma
NCT02201420	PHASE2	COMPLETED	Evaluation of Tc 99m Tilmanocept Localization in Primary Cutaneous Kaposi’s Sarcoma and Lymphatic Drainage by SPECT/CT
NCT02229981	PHASE1/PHASE2	WITHDRAWN	Early Phase Evaluation of ABC294640 in Patients With Refractory/Relapsed Diffuse Large B-cell Lymphoma or Kaposi Sarcoma
NCT03077451	PHASE2	COMPLETED	Nelfinavir Mesylate in Treating Patients With Kaposi Sarcoma
NCT03296553	PHASE2	COMPLETED	Impact of Valganciclovir on Severe IRIS-Kaposi Sarcoma Mortality: an Open-label, Parallel, Randomized Controlled-trial.
NCT03469804	PHASE2	UNKNOWN	Phase II Multicentric Study of Pembrolizumab in Classic or Endemic Kaposi’s Sarcoma
NCT03993106	PHASE2	UNKNOWN	A Study of sEphB4-HSA in Kaposi Sarcoma
NCT04065152	PHASE2	UNKNOWN	Phase II Multicenter Study of Talimogene Laherparepvec in Classic or Endemic Kaposi Sarcoma
NCT05329792	PHASE2	UNKNOWN	L19IL2/L19TNF in Skin Cancer Patients
NCT05846724	PHASE2	WITHDRAWN	Pembrolizumab Plus Lenvatinib in Previously Treated Classic Kaposi Sarcoma
NCT02659930	PHASE1	ACTIVE_NOT_RECRUITING	Pomalidomide in Combination With Liposomal Doxorubicin in People With Advanced or Refractory Kaposi Sarcoma
NCT04514484	PHASE1	ACTIVE_NOT_RECRUITING	Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
NCT04902443	PHASE1	RECRUITING	Pomalidomide and Nivolumab in People With Virus-Associated Malignancies With or Without HIV
NCT05859074	PHASE1	RECRUITING	A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
PROPRANOLOL	4	4
NELFINAVIR	4	3
TENOFOVIR DISOPROXIL	4	3
VALGANCICLOVIR	4	2
CABOZANTINIB S-MALATE	4	1
EFAVIRENZ	4	1
IXAZOMIB CITRATE	4	1
LAMIVUDINE	4	1
LOPINAVIR	4	1
MARAVIROC	4	1
PACRITINIB	4	1
POMALIDOMIDE	4	1
TALIMOGENE LAHERPAREPVEC	4	1
VISMODEGIB	4	1
TENOFOVIR ANHYDROUS	3	3
BINTRAFUSP ALFA	3	1
L19IL2	3	1
ONFEKAFUSP ALFA	3	1
ABC-294640	2	1
DARLEUKIN	2	1
EFINEPTAKIN ALFA	2	1
HALOFUGINONE HYDROBROMIDE	2	1
INTERLEUKIN-12 HUMAN RECOMBINANT	2	1
INTERLEUKIN-7	2	1
SEPHB4-HSA	2	1
CHEMBL207216	0	1
CHEMBL2163486	0	1
CHEMBL361331	0	1
CHEMBL5413158	0	1
CHEMBL584744	0	1